Welcome to Psynova Neurotech

Psynova Neurotech is exclusively focused on the commercial development and exploitation of novel biomarkers for Neuropsychiatric and other mental illnesses.

Building on 12 years of ground-breaking research by its founder Dr Sabine Bahn, Psynova Neurotech is initially concentrating on Schizophrenia and Bipolar Affective Disorder.

Media Centre

Biomarkers trump behavior in mental illness diagnosis

Here’s how doctors decide which mental or neurological disorder their troubled patients suffer from: they ask questions like, “Are you hearing voices?” and “Do you feel like people are out to get you?”

Not all that different from how they used to do it about 100 years ago.

New techniques are set to radically change that approach—and perhaps define new categories within each disease—relying more on changes in physiology than in behavior. [read the full article]